160 related articles for article (PubMed ID: 10465342)
1. CD24 is a marker for human breast carcinoma.
Fogel M; Friederichs J; Zeller Y; Husar M; Smirnov A; Roitman L; Altevogt P; Sthoeger ZM
Cancer Lett; 1999 Aug; 143(1):87-94. PubMed ID: 10465342
[TBL] [Abstract][Full Text] [Related]
2. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?
Hofman P; Hsi BL; Manie S; Fenichel P; Thyss A; Rossi B
Breast Cancer Res Treat; 1994; 32(2):213-9. PubMed ID: 7532466
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
Zheng WQ; Looi LM; Cheah PL
Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
[TBL] [Abstract][Full Text] [Related]
4. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells.
Aigner S; Sthoeger ZM; Fogel M; Weber E; Zarn J; Ruppert M; Zeller Y; Vestweber D; Stahel R; Sammar M; Altevogt P
Blood; 1997 May; 89(9):3385-95. PubMed ID: 9129046
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
6. CD24 mediates rolling of breast carcinoma cells on P-selectin.
Aigner S; Ramos CL; Hafezi-Moghadam A; Lawrence MB; Friederichs J; Altevogt P; Ley K
FASEB J; 1998 Sep; 12(12):1241-51. PubMed ID: 9737727
[TBL] [Abstract][Full Text] [Related]
7. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
8. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
9. Survivin in breast lesions: immunohistochemical analysis of 196 cases.
Adamkov M; Drahošová S; Chylíková J; Výbohová D
Pol J Pathol; 2017; 68(4):297-305. PubMed ID: 29517199
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin intermediate filament expression in benign and malignant breast disease.
Heatley M; Maxwell P; Whiteside C; Toner P
J Clin Pathol; 1995 Jan; 48(1):26-32. PubMed ID: 7535804
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
12. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
13. Vimentin expression in benign and malignant breast epithelium.
Heatley M; Whiteside C; Maxwell P; Toner P
J Clin Pathol; 1993 May; 46(5):441-5. PubMed ID: 7686566
[TBL] [Abstract][Full Text] [Related]
14. [Expression of T and Tn antigens in breast cancers].
Konska G; Favy D; Guillot J; Bernard-Gallon D; de Latour M; Fonck Y
C R Seances Soc Biol Fil; 1998; 192(4):733-47. PubMed ID: 9842474
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
16. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
[TBL] [Abstract][Full Text] [Related]
17. Cell surface CD44v5 levels correlate with progesterone receptors and a tumor size > 2 cm in infiltrating ductal carcinomas of the breast.
Nuñez MI; Arias JI; Del Rio MC; Martinez MI; Alba A; Allende MT; Ruibal A
Int J Biol Markers; 1996; 11(4):220-2. PubMed ID: 9017447
[No Abstract] [Full Text] [Related]
18. Mean nuclear area and metallothionein expression in ductal breast tumors: correlation with estrogen receptor status.
El Sharkawy SL; Farrag AR
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):108-12. PubMed ID: 18227734
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of CD44
Da Cruz Paula A; Leitão C; Marques O; Rosa AM; Santos AH; Rêma A; de Fátima Faria M; Rocha A; Costa JL; Lima M; Lopes C
Virchows Arch; 2017 Mar; 470(3):311-322. PubMed ID: 28116522
[TBL] [Abstract][Full Text] [Related]
20. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
